Drugs / AZD2327
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00759395 | Jan 2009 → Oct 2011 | major depressive disorder | AstraZeneca | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2327 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00759395 ↗ |
| Action | Activate | “AZD2327 is a selective delta opioid receptor (DOR) agonist with anxiolytic and antidepressant activity in animal models.” PMID 26728893 ↗ Jan 2016 |
| Route | Oral | “Tablet, Oral, Daily” NCT00759395 ↗ |